申请人:AxoGlia Therapeutics S.A.
公开号:EP2112145A1
公开(公告)日:2009-10-28
Compounds of general formula (I) and (II)
in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14 and R15 have the meanings given in the specification, are useful in the treatment of neurodegenerative disease.
通式(I)和(II)的化合物
其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14和R15具有规范中给定的含义,在神经退行性疾病的治疗中是有用的。